Market Overview:
The global tumor necrosis factor receptor superfamily member 9 (TNFR9) market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of cancer, rising R&D investments for novel TNFR9 therapies, and growing awareness about TNFR9-targeted therapies. Based on type, the global TNFR9 market is segmented into ultra-41BBL, PRS-342, ISAS-01, EU-101 and others. Ultra 41BBL dominates the global TNFR9 market owing to its high specificity and affinity for human TNF receptors. In terms of application, gastric cancer accounts for the majority share in the global TNFR9 market followed by bladder cancer and cervical cancer. However, lymphoma is expected to grow at a highest CAGR during the forecast period owing to increasing incidence rates of lymphoma across different regions worldwide.
Product Definition:
Tumor necrosis factor receptor superfamily member 9 (TNFR9) is a protein that in humans is encoded by the TNFR9 gene. The protein encoded by this gene is a member of the tumor necrosis factor receptor superfamily. This protein binds to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and may play a role in apoptosis.
Ultra-41BBL:
Ultra-41BBL is a type of BCL-1 protein, which is produced in response to tumor necrosis factor (TNF). It has been observed that the level of 41BBL protein increases rapidly in patients suffering from inflammatory and autoimmune diseases. Thus, it has become an important biomarker for several chronic diseases including rheumatoid arthritis, psoriasis, cancer and others.
PRS-342:
PRS-342 is a selective inhibitor of tumor necrosis factor (TNF) receptor superfamily member 9. It has been reported to have high oral bioavailability and excellent pharmacokinetics in humans. The compound was developed by Pfizer as an anti-inflammatory drug for the treatment of Crohn's disease and rheumatoid arthritis, but was found to be effective against cancer cell lines in vitro when tested at concentrations lower than those required for efficacy.
Application Insights:
The gastric cancer segment dominated the global tumor necrosis factor receptor superfamily member 9 market in terms of revenue in 2017. This is due to the high prevalence of this disease and increasing research & development activities pertaining to its treatment. For instance, in March 2018, Pfizer announced that it has received U.S. FDA approval for Taltz (ixekizumab) injection for the treatment of patients with non-small cell lung cancer (NSCLC) who have been treated with chemotherapy or who are candidates for surgery or radiotherapy and have a histological diagnosis consistent with NSCLS as well as an Eastern Cooperative Oncology Group study performance status of 0 or 1.
TNFRSF9 was found to be highly effective against various types of cancers such as bladder, breast, skin melanoma/solar keratosis, head & neck cancer and others like pancreatic cancer and Non-small Cell Lung Cancer (NSCLC).
Regional Analysis:
North America dominated the global tumor necrosis factor receptor superfamily member 9 market with a revenue share of 48.2% in 2017. This is due to the presence of key players, increased adoption of immunotherapies and rising incidence rates for cancer in this region. Moreover, increasing government funding for oncology therapeutics is also expected to drive growth during the forecast period. For instance, according to data published by National Cancer Institute (NCI), from fiscal years 2011 through 2015, NCI invested USD X million in research grants and contract support activities related to immunotherapy agents including TNFRSF9 molecules for advanced clinical development or additional study/trials specific for these molecules as an add-on therapy after other treatment failed or alone as primary therapy among patients with metastatic breast cancer who have received at least two lines of prior systemic therapy).
Growth Factors:
- Increasing incidence of cancer
- Growing awareness about the benefits of Tumor Necrosis Factor Receptor Superfamily Member 9 therapy
- Rising demand for targeted therapies
- Technological advancements in Tumor Necrosis Factor Receptor Superfamily Member 9 treatment
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Tumor Necrosis Factor Receptor Superfamily Member 9 Market Research Report
By Type
Ultra-41BBL, PRS-342, ISAS-01, EU-101, Others
By Application
Gastric Cancer, Bladder Cancer, Cervical Cancer, Lymphoma, Others
By Companies
Agenus Inc, Alligator Bioscience AB, Apogenix GmbH, BioInvent International AB, Eli Lilly and Co, Juno Therapeutics Inc, MacroGenics Inc, Pfizer Inc, Pieris Pharmaceuticals Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
202
Number of Tables & Figures
142
Customization Available
Yes, the report can be customized as per your need.
Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Report Segments:
The global Tumor Necrosis Factor Receptor Superfamily Member 9 market is segmented on the basis of:
Types
Ultra-41BBL, PRS-342, ISAS-01, EU-101, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gastric Cancer, Bladder Cancer, Cervical Cancer, Lymphoma, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Agenus Inc
- Alligator Bioscience AB
- Apogenix GmbH
- BioInvent International AB
- Eli Lilly and Co
- Juno Therapeutics Inc
- MacroGenics Inc
- Pfizer Inc
- Pieris Pharmaceuticals Inc
Highlights of The Tumor Necrosis Factor Receptor Superfamily Member 9 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Ultra-41BBL
- PRS-342
- ISAS-01
- EU-101
- Others
- By Application:
- Gastric Cancer
- Bladder Cancer
- Cervical Cancer
- Lymphoma
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tumor Necrosis Factor Receptor Superfamily Member 9 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
TNFRSF9 is a protein that belongs to the tumor necrosis factor receptor superfamily. TNFRSF9 is specifically responsible for mediating the inflammatory response in cells.
Some of the major companies in the tumor necrosis factor receptor superfamily member 9 market are Agenus Inc, Alligator Bioscience AB, Apogenix GmbH, BioInvent International AB, Eli Lilly and Co, Juno Therapeutics Inc, MacroGenics Inc, Pfizer Inc, Pieris Pharmaceuticals Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tumor Necrosis Factor Receptor Superfamily Member 9 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size & Forecast, 2020-2028
4.5.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size and Y-o-Y Growth
4.5.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Ultra-41BBL
5.2.2 PRS-342
5.2.3 ISAS-01
5.2.4 EU-101
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Gastric Cancer
6.2.2 Bladder Cancer
6.2.3 Cervical Cancer
6.2.4 Lymphoma
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Ultra-41BBL
9.6.2 PRS-342
9.6.3 ISAS-01
9.6.4 EU-101
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Gastric Cancer
9.10.2 Bladder Cancer
9.10.3 Cervical Cancer
9.10.4 Lymphoma
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Ultra-41BBL
10.6.2 PRS-342
10.6.3 ISAS-01
10.6.4 EU-101
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Gastric Cancer
10.10.2 Bladder Cancer
10.10.3 Cervical Cancer
10.10.4 Lymphoma
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Ultra-41BBL
11.6.2 PRS-342
11.6.3 ISAS-01
11.6.4 EU-101
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Gastric Cancer
11.10.2 Bladder Cancer
11.10.3 Cervical Cancer
11.10.4 Lymphoma
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Ultra-41BBL
12.6.2 PRS-342
12.6.3 ISAS-01
12.6.4 EU-101
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Gastric Cancer
12.10.2 Bladder Cancer
12.10.3 Cervical Cancer
12.10.4 Lymphoma
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Ultra-41BBL
13.6.2 PRS-342
13.6.3 ISAS-01
13.6.4 EU-101
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Gastric Cancer
13.10.2 Bladder Cancer
13.10.3 Cervical Cancer
13.10.4 Lymphoma
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Market: Competitive Dashboard
14.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Agenus Inc
14.3.2 Alligator Bioscience AB
14.3.3 Apogenix GmbH
14.3.4 BioInvent International AB
14.3.5 Eli Lilly and Co
14.3.6 Juno Therapeutics Inc
14.3.7 MacroGenics Inc
14.3.8 Pfizer Inc
14.3.9 Pieris Pharmaceuticals Inc
